Cladribine — Drug Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

5 Recruiting

6 Completed trials

14 Sponsors

20 Countries

Phase III

Phase II

Phase IV

Phase III: 4 Phase II/III: 1 Phase II: 5 Phase IV: 4

Oversight events:

1 temporary halt across 1 trial

View oversight register →

Indications tested

Multiple sclerosis 3 Myasthenia gravis 2 Acute myeloid leukaemia 1 Myelodysplastic syndrome 1 Secondary progressive multiple sclerosis 1 Hairy cell leukaemia 1 Relapsing-remitting multiple sclerosis 1

Sponsors using this IMP

Aristotle University Of Thessaloniki 1 Helse Bergen HF 1 Instytut Psychiatrii I Neurologii 1 Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. 1 María Luisa Martínez Ginés 1 Medical University Of Lodz 1 Medizinische Hochschule Hannover 1 Merck Healthcare KGaA 1 Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy 1 Region Uppsala 1 St. Anna Childrens Cancer Research Institute GmbH 1 Universita' Degli Studi Di Perugia 1

All trials

14 total

HiHat trial Pending

2024-519700-28-01 Phase II 1 country Region Uppsala
Effects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS. Pending

2025-521910-24-00 Phase IV 1 country Aristotle University Of Thessaloniki
IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting

2024-514517-35-00 Phase III 7 countries Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla… Recruiting

2023-507746-83-00 Phase III 12 countries Merck Healthcare KGaA
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua… Recruiting

2024-512503-39-00 Phase IV 3 countries Medizinische Hochschule Hannover
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leu… Recruiting

2023-503394-37-00 Phase III 1 country Medical University Of Lodz
VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEM… Recruiting

2024-520119-41-00 Phase II 1 country Universita' Degli Studi Di Perugia
Cladribine for the treatment of secondary progressive MS - randomized, double-blind, placebo-controlled study. Ended

2024-516992-33-02 Phase II 1 country Instytut Psychiatrii I Neurologii
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended

2024-512676-36-00 Phase II/III 12 countries St. Anna Childrens Cancer Research Institute GmbH
Assessment of tolerance and effectiveness of total body irradiation and cladribine before allogeneic hematopoietic cell transplantation in p… Ended

2024-517477-24-00 Phase II 1 country Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada…
Cladribine therapy in Myasthenia Ended

2024-517083-32-00 Phase II 1 country Uniwersytet Medyczny W Lublinie
Effect of cladribine treatment on microglial activation in the CNS Ended

2024-519921-39-00 Phase IV 1 country Varsinais-Suomen hyvinvointialue
RAM-MS Ended

2024-510630-40-00 Phase III 4 countries Helse Bergen HF
A phase IV, unicentric, open label clinical trial to evaluate the default mode network in multiple sclerosis patients on Cladribine treatmen… Expired

2023-504577-21-00 Phase IV 1 country María Luisa Martínez Ginés

Showing 1–14 of 14 trials

← All drugs A–Z